Blog

qordata thought leaders and subject matter experts share their insights and experiences

Ned Mumtaz
Written By
Ned Mumtaz
June 5, 2017
0 Comments

Pharma Compliance professionals—like everyone else managing copious amounts of data—will be directly affected by the enforcement of GDPR (General Data Protection Regulation) in May 2018. In this blog, we describe the most important reason for compliance programs to start internalizing process changes introduced by GDPR. GDPR: Why It’s Critical For Transparency/Compliance Professionals As our clients and friends in the pharma industry will confirm, reputational risk—and its preceding penalties–are a compliance professional’s worst nightmare. In previous posts, qordata has described how fines, CMPs (Civil Monetary Penalties) and CIAs (Corporate Integrity Agreements) strike directly at short term sales, and take a longer hit at brand value and equity, goodwill and customer loyalty. Big, Bad Pharma—Now The Cost Is Higher Europe is no […]

Ned Mumtaz
Written By
Ned Mumtaz
May 22, 2017
0 Comments

In the first week of May, qordata invited Dr. Klaus Geltsetzer to speak on how to “Determine the Relationships of Different Global Disclosure Requirements.”  He gave a comprehensive description of compliance efforts across the world, in which transparency and disclosure efforts in Germany yielded some surprising insights. Germany: Bad Boy Or Poster Child Of The Transparency Movement? As Dr. Geltsetzer stated in the webinar, the physician consent rate in Germany hovers close to 30%. In other words, only 1 in 3 physicians agrees to having his/her ToV data published. This means that of the 71,000 HCPs registered in Deutschland, the majority choose not to disclose their individual ToVs (Transfer of Value). What does that mean for transparency? In the €575m […]

Nayyara Rahman
Written By
Nayyara Rahman
May 22, 2017
0 Comments

In our previous post on Dr. Klaus Geltsetzer’s webinar presentation, how to “Determine the Relationships of Different Global Disclosure Requirements” we described how Germany’s consent rates tell an interesting story, depending on how they’re calculated. We’re resuming the debate on Germany’s position in the pharmaceutical transparency space. This time, we discuss industry-led, private sector synergy. Or lack thereof. As we learnt, thanks to Dr. Klaus Geltsetzer, there are ‘several’ Pharma associations in Europe. Prominent amongst these are: vfa (ca. 150 members) BPI (ca. 240 members) BAH (> 450 members) Pro generica (16 members) That’s an impressive number for one country. It also shows a determined, national effort towards improving pharmaceutical disclosure. Or does it? As Dr. Geltsetzer mentioned, there are over 300 […]

Nayyara Rahman
Written By
Nayyara Rahman
May 19, 2017
0 Comments

Synergy between pharma associations may never materialize. It may even backfire. We will be elaborating on this in an upcoming post, with the real-life case of pharma disclosure in Germany. Today we discuss how public interest has surfaced as a surprisingly powerful ally in the pharma transparency movement.  Before exploring the ‘whats’ and ‘hows’, we would like to talk a little about why ordinary citizens would take interest in something like pharmaceutical spend. Public Interest An obvious answer, public interest. Citizens have a right to know the composition of public and private healthcare. They need to know the components of decisions related to treatment options available to them. In this, the importance of physician-pharma relationships can be illustrated by this […]

Upcoming Event

11th Annual Forum on Transparency & Aggregate Spend

14 Aug to 16 Aug, 2017
8:00 am To 6:00 pm EST
DETAILS

Ask an Expert

Get all the insights, and the answers to the most critical issues in pharma compliance from thought leaders in qorcommunity

Get Answer
OUR SOLUTIONS CAN SIMPLIFY YOUR COMPLIANCE EFFORTS.